Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient

Cancer Cell. 2021 Aug 9;39(8):1037-1038. doi: 10.1016/j.ccell.2021.06.015. Epub 2021 Jun 26.

Authors

Joshua A Hill¹, Chaitra S Ujjani², Alexander L Greninger³, Mazyar Shadman², Ajay K Gopal²

Affiliations

¹ Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA; Seattle Cancer Care Alliance, Seattle, WA, USA. Electronic address: jahill3@fredhutch.org.
² Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA; Seattle Cancer Care Alliance, Seattle, WA, USA.
³ Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA.

No abstract available

Keywords: COVID-19; SARS-CoV-2; booster; hematologic malignancy; vaccine.

Publication types

Letter
Comment

MeSH terms

COVID-19 Vaccines
COVID-19*
Humans
Lymphoma*
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines